What's Happening?
Lannett Company, Inc., along with its subsidiary Lanexa Biologics and partner Sunshine Lake Pharma, has received approval from the U.S. Food and Drug Administration (FDA) for LANGLARA, an interchangeable
biosimilar to Lantus (insulin glargine). This approval allows LANGLARA to be used for treating adults and pediatric patients with type 1 diabetes mellitus and adults with type 2 diabetes mellitus. The FDA's interchangeability designation means that pharmacists can substitute LANGLARA for Lantus without needing prescriber intervention, depending on state laws. The approval was based on comprehensive studies confirming LANGLARA's efficacy, safety, and immunogenicity compared to Lantus. The product will be manufactured by Sunshine Lake Pharma and distributed in the U.S. through Lanexa Biologics.
Why It's Important?
The approval of LANGLARA as an interchangeable biosimilar is significant as it addresses the high cost and limited availability of insulin, a critical issue for diabetes patients. By providing a more affordable alternative, Lannett aims to expand access to essential diabetes treatment. The interchangeability designation is crucial for patient access, as it simplifies the process for pharmacists to provide this alternative without additional prescriptions. This development could lead to increased competition in the insulin market, potentially driving down prices and improving accessibility for patients. The partnership between Lannett and Sunshine Lake Pharma highlights a strategic effort to leverage large-scale manufacturing capabilities to meet the demand for affordable insulin.
What's Next?
Following the FDA approval, Lannett and Lanexa Biologics plan to pursue broad formulary placement across all commercial channels to ensure LANGLARA is accessible to patients. The companies are also collaborating on developing a short-acting insulin aspart, which is currently in the pipeline. Additionally, Lannett is set to be acquired by Aurobindo Pharma, which will result in Lanexa becoming a stand-alone company. This acquisition could further enhance Lannett's capabilities and market reach in the biosimilar space. Stakeholders, including healthcare providers and insurers, will likely monitor the impact of LANGLARA's introduction on the insulin market and patient outcomes.
